Intensive Care Medicine

, Volume 36, Issue 7, pp 1213–1220 | Cite as

Infusion fluids contain harmful glucose degradation products

  • Anna Bryland
  • Marcus Broman
  • Martin Erixon
  • Bengt Klarin
  • Torbjörn Lindén
  • Hans Friberg
  • Anders Wieslander
  • Per Kjellstrand
  • Claudio Ronco
  • Ola Carlsson
  • Gabriela Godaly
Open Access
Original

Abstract

Purpose

Glucose degradation products (GDPs) are precursors of advanced glycation end products (AGEs) that cause cellular damage and inflammation. We examined the content of GDPs in commercially available glucose-containing infusion fluids and investigated whether GDPs are found in patients’ blood.

Methods

The content of GDPs was examined in infusion fluids by high-performance liquid chromatography (HPLC) analysis. To investigate whether GDPs also are found in patients, we included 11 patients who received glucose fluids (standard group) during and after their surgery and 11 control patients receiving buffered saline (control group). Blood samples were analyzed for GDP content and carboxymethyllysine (CML), as a measure of AGE formation. The influence of heat-sterilized fluids on cell viability and cell function upon infection was investigated.

Results

All investigated fluids contained high concentrations of GDPs, such as 3-deoxyglucosone (3-DG). Serum concentration of 3-DG increased rapidly by a factor of eight in patients receiving standard therapy. Serum CML levels increased significantly and showed linear correlation with the amount of infused 3-DG. There was no increase in serum 3-DG or CML concentrations in the control group. The concentration of GDPs in most of the tested fluids damaged neutrophils, reducing their cytokine secretion, and inhibited microbial killing.

Conclusions

These findings indicate that normal standard fluid therapy involves unwanted infusion of GDPs. Reduction of the content of GDPs in commonly used infusion fluids may improve cell function, and possibly also organ function, in intensive-care patients.

Keywords

Glucose Infusion fluids Toxicity Advanced glycation end products Neutrophils Innate defense Cell survival 

Introduction

Isotonic glucose solutions are frequently used in intensive care units (ICUs) to hydrate patients with acute disease or after surgery. These commercially available fluids contain between 2.5% and 50% glucose and are heat-sterilized to assure sterility of the products. Beyond hydration, these sterile products provide calories. Dysregulated glucose homeostasis occurs frequently in critically ill patients, but strict glycemic control does not decrease infectious morbidity, mortality, and length of stay in the ICU [1, 2, 3, 4]. Glucose is seen as an inexpensive and secure source of energy on the one hand, and as a harmful substance on the other. What is perhaps less known is that the sterilization process of these fluid products leads to degradation of the glucose to highly bioreactive glucose degradation products (GDPs).

Glucose is used as an osmotic agent in fluids for peritoneal dialysis (PD) to remove water from patients with renal failure. Heat-sterilization of glucose-containing PD fluids promotes formation of a large number of GDPs [5]. Several GDPs, such as 3-deoxyglucosone (3-DG), 3,4-dideoxyglucosone-3-ene (3,4-DGE), 5-hydroxymethyl-2-furaldehyde (5-HMF), and formaldehyde, have been identified in PD fluids [6, 7]. At the cellular level, aldehydes disrupt cell signaling and cause extensive damage to membrane lipids, cellular proteins, mitochondrial function, RNA, and DNA [8]. The most bioreactive GDP in heat-sterilized PD solutions is 3,4-DGE [7]. This toxic molecule was found to impair wound healing and to induce apoptosis in human leukocytes and renal epithelial cells [9, 10, 11]. Highly reactive GDPs, such as 3,4-DGE, react instantly with different molecules, while others, such as 3-DG and 5-HMF, remain in circulation [12].

After reaching the blood, GDPs bind to serum proteins, which gives rise to advanced glycation end products (AGE) [13]. AGEs are known to be involved in oxidative stress and are associated with cardiovascular morbidity and renal injury [14, 15, 16]. By using new manufacturing techniques, PD solutions with low GDP content have been produced [17, 18]. Such low-GDP PD solutions have been shown to reduce serum AGE levels [13, 19] and decrease serum 3-DG concentrations [20]. Several other clinical studies have demonstrated that removal of GDPs from fluids leads to decreased inflammation, preserved kidney function, and improved patient outcomes [19, 21, 22, 23].

In order to evaluate whether isotonic glucose-containing infusion fluids include toxic GDPs, we examined the content of such substances in commercially available glucose solutions and the effect they exhibited on neutrophil function. Furthermore, we analyzed patients’ blood for GDPs and CML after receiving standard glucose-containing fluid therapy in the postoperative setting and compared the serum levels with those of patients receiving buffered saline.

Methods

Fluids

Seven different brands of glucose-containing infusion fluids, which are routinely used in the ICU setting at Lund University Hospital (Lund, Sweden), were investigated (Table 1).
Table 1

Content of GDPs in the investigated infusion fluids

Number

Name

Company

Glucose (%)

GDP concentrations (μM)b (mean ± SEM)

3-DG

3,4-DGE

5-HMF

Formaldehyde

1

Glucos Fresenius 200

Fresenius Kabi AB

20

583 ± 9.7

59 ± 1.2

105 ± 7.7

19 ± 3.4

2

Glucos Fresenius 300

Fresenius Kabi AB

30

790 ± 21.7

56 ± 2.3

146 ± 7.1

34 ± 4.7

3

Rehydrex

Fresenius Kabi AB

2.5

141 ± 0.7

22 ± 1.1

2 ± 0.2

17 ± 0.7

4

Glucos Baxter

Baxter Medical AB

10

400 ± 9.7

50 ± 0.1

42 ± 1.6

10 ± 3.0

5

Glucos Baxter 25/50

Baxter Medical AB

2.5

123 ± 0.8

22 ± 0.2

2 ± 0.1

10 ± 1.1

6

Glucos BaxterViaflo

Baxter Medical AB

5

238 ± 3.9

35 ± 0.6

17 ± 0.4

4 ± 1.2

7

Glucos Baxter Na40 K20

Baxter Medical AB

10

358 ± 5.4

59 ± 0.4

10 ± 0.3

21 ± 2.8

LC50a

   

1,374 ± 47.9

47 ± 2.7

2,463 ± 64.2

44 ± 5.1

aLC50 is the concentration (μM) of GDPs that kills 50% of neutrophils

bEach value represents the mean ± standard error of the mean (SEM) (n = 3)

Patients

The study was approved by the Regional Ethical Review Board (DNR 207/2007) of Lund University, Sweden. After patients gave written informed consent to be included in the study, 11 patients (6 women and 5 men) receiving glucose-containing postoperative infusion fluids were included in the standard group, and 11 patients (6 women and 5 men) receiving buffered saline (Ringer’s acetate) were included in the control group. Serum was analyzed for GDPs and CML.

Studies of effects of GDPs on cell viability and cell function

Cell viability was determined on isolated human neutrophils using the Thiazolyl blue tetrazolium bromide (MTT) assay. As an experimental infection model, neutrophils were infected with E. coli in the presence of GDPs or with infusion fluids 2 and 3 or their respective sterile filtered control fluids. Secretion of CXCL8 and interleukin 6 (IL-6) by the infected neutrophils was quantified in supernatants by enzyme-linked immunosorbent assay (ELISA, RD Systems Europe). Capacity of neutrophil microbial killing was measured by Fc-OxyBURST (Invitrogen) according to the manufacturer’s instructions.

Detailed methods are described in the Electronic Supplementary Material.

Results

GDPs found in all investigated infusion fluids

In all of the tested fluids, 3-DG, 3,4-DGE, 5-HMF, and formaldehyde were found (Table 1). The concentration of 3-DG varied from 123 to 790 μM, of 3,4-DGE from 22 to 59 μM, of 5-HMF from 2 to 146 μM, and of formaldehyde from 4 to 34 μM (Table 1). The concentration of methylglyoxal was between 7 and 17 μM in fluids 3 and 5–7, but below the detection limit (1.0 μM) for the rest of the fluids. Acetaldehyde was only found in fluids 3, 5, and 7, at very low concentrations (1–2 μM) and close to the limit of detection (<1.1 μM). Glyoxal concentration was below the detection limit (3.4 μM) in most of the fluids, except fluid 3 that contained 31 μM. The concentrations of acetaldehyde, methylglyoxal, and glyoxal were far lower than the LC50 values [7, 24]. The concentrations of GDPs in sterile filtered control fluids were below the limit of detection.

GDPs in blood circulation

To ascertain whether the GDPs in glucose-containing infusion fluids could be found in patient blood circulation, we investigated patients who received glucose-containing fluids (2.5% or 5%; numbers 5 and 6 in Table 1) within their normal treatment (standard group) and compared them with the control group who did not receive the glucose-containing fluids (Fig. 1). Levels of 3-DG, 3,4-DGE, formaldehyde, and 5-HMF were measured in serum samples before infusion and after 0.5, 3, 6, and 9 h.
Fig. 1

GDPs found in patient serum. Concentration of 3-DG (μM) in serum of patients receiving glucose-containing infusion fluids and the control group: before infusion (0 h), mean values during infusion (0.5–6 h), and at the end of infusion (9 h). The amount of serum 3-DG increased rapidly after infusion of glucose-containing infusion fluids and did not reach the background level even after 9 h. The control group showed significantly less variability of serum 3-DG concentrations throughout the study. The statistical difference between the groups was calculated with Mann–Whitney/Student t test (ns nonsignificant, **P < 0.01, ***P ≤ 0.001)

Before infusion the serum from all patients in the standard group and in the control group contained normal amounts of 3-DG (approximately 0.2 μM; Fig. 1; Table 2). The amount of serum 3-DG in the standard group increased immediately after infusion and declined slowly thereafter, but had not reached the background level after 9 h. There were some differences in individual serum levels of 3-DG that could not be correlated to the amount of infusions, clearance or the glucose content of the infused solutions. There was no increase in the amount of serum 3-DG in the control group. In addition, we found a significant difference between the groups during the infusion (P ≤ 0.001) and at the end of the infusion (P = 0.004). The amount of 5-HMF in the standard group was at a normal concentration of 0.87 μM at the start of the study [25], increased steadily after infusion, and reached a maximum after 9 h (1.75 μM). The serum concentration of 5-HMF was doubled at the end of the study, but we could not find any statistical difference between the groups. The amount of 5-HMF in the control patients was below the limit of detection (1.0 μM) throughout the study. None of the more reactive GDPs, 3,4-DGE and formaldehyde, could be detected in the serum from any patients.
Table 2

Serum concentrations (μM) of 3-DG in patients receiving the glucose-containing infusion fluids

Time (h)

0

0.5

3

6

9

Mean

0.19

1.54

0.48

0.50

0.50

SEM

0.02

0.19

0.10

0.09

0.08

P

 

<0.001

0.002

0.006

<0.001

Significance values were evaluated by one-way analysis of variance, Dunn comparisons test, and Mann–Whitney/Student t test

Urinary GDP levels

Patients’ urine was collected throughout the study for analysis of GDPs. Urine concentrations were then compared with the amount of 3,4-DGE, 3-DG, and 5-HMF that the patient group received during their therapy (see Supplementary Fig. 1). An average patient in the standard group received approximately 1.7 l infusion fluids, which contained 47 mg 3-DG, 7 mg 3,4-DGE, 2 mg 5-HMF, and 0.4 mg formaldehyde. A tenth of the infused 3-DG was found in the urine (4.5 mg, P = 0.0002), while the amount of 5-HMF was four times higher (8.7 mg, P = 0.0314) than the infused amount. We found no 5-HMF in the control group and on average 0.1 mg 3-DG (P ≤ 0.001 compared with the patient group, data not shown). No 3,4-DGE or formaldehyde was found in urine.

AGE formation

We found a linear correlation between the infused 3-DG and the increased CML formation (see Supplementary Fig. 2) in the standard group. Nine hours after receiving the initial treatment with infusion fluids, the patients showed a significant increase of CML in serum (Fig. 2). There was no increase in serum CML formation in the control group (P ≤ 0.001).
Fig. 2

Serum CML concentrations. Time dependency of the CML serum concentrations in patients after receiving the infusion fluids and in the control group. Data are shown as mean ± SEM; *P < 0.05, **P < 0.01, ***P ≤ 0.001

Heat-sterilized infusion fluids reduce cell viability

The difference between infusion fluids and control fluids is shown in Fig. 3. All fluids were diluted to physiological levels, as regards osmolarity and glucose, before they were incubated with neutrophils (Fig. 3). The table illustrates the content of GDPs in the diluted fluids. Even though the fluids were substantially diluted, we found that all but one of the investigated infusion fluids significantly decreased cell viability compared with control fluids. Fluid 2, which originally contained the highest glucose concentration and hence was diluted most (1:15), was the one that was least harmful to neutrophils.
Fig. 3

Heat-sterilized infusion fluids reduce cell viability. Commercial heat-sterilized infusion fluids were compared with the control fluids. The figure shows the difference in cell survival between neutrophils treated with infusion fluids or with sterile filtered control fluids after 4 h of incubation. Mean of seven separate experiments (±SEM). The fluids were diluted to achieve physiological concentrations of glucose (2%) and osmolarity (285 mOsm/l). Concentrations of the GDPs in the diluted fluids are presented in the table in the figure. Statistical difference between heat-sterilized infusion fluids and control fluids was calculated with Mann–Whitney test/Student t test (*P < 0.05, **P < 0.01, ***P < 0.001, ns nonsignificant)

Dose response and lethal concentrations

To investigate the influence of GDPs on human cells, neutrophils were incubated with different concentrations of 3,4-DGE, 3-DG, and 5-HMF. The lethal concentration of GDPs that killed 50% of neutrophils (LC50) was compared with the concentration of GDPs found in the infusion fluids (Table 1). The LC50 value for the most reactive GDPs, 3,4-DGE and formaldehyde, was 47 and 44 μM, respectively. The majority of the investigated fluids contained higher concentrations of 3,4-DGE than 47 μM (Table 1). The LC50 value for the less reactive molecules 3-DG and 5-HMF was higher, 1,374 μM and 2,463 μM, respectively.

GDPs diminished the inflammatory response

The possible immunomodulatory role of GDPs was investigated by measuring CXCL8 and IL-6 secretion upon bacterial infection. E. coli infection of human neutrophils induced secretion of both inflammatory cytokines (see Supplementary Figs. 3 and 4). Normal background cytokine production in uninfected neutrophils was 99 ± 4 pg/ml for CXCL8 and 63 ± 20 pg/ml for IL-6. The background production was set at zero in Supplementary Figs. 3 and 4. The presence of GDPs, at the same concentration that was found in an average infusion fluid, clearly suppressed secretion of both CXCL8 and IL-6. CXCL8 secretion was reduced by 57% with formaldehyde, 43% with 3,4-DGE, 33% with 3-DG, and 30% with 5-HMF. CXCL8 secretion was also inhibited with the physiologically diluted fluids 2 and 3 (10% and 38%, respectively) (see Supplementary Fig. 3), suggesting a correlation with their content of GDPs. Neutrophil IL-6 secretion upon infection was suppressed in the presence of formaldehyde, 3,4-DGE, and 3-DG (98%, 72%, and 59%, respectively) compared with the positive control (Fig. 4). A smaller inhibitory effect (28%) was found with 5-HMF. The diluted fluid 3, with the highest content of GDPs, suppressed IL-6 secretion by 73%, while the more diluted fluid 2 was less inhibitory (10%). The sterile filtered control fluids were not found to inhibit neutrophil cytokine secretion.
Fig. 4

GDPs modulate the inflammatory response. Human neutrophils were infected with E. coli for 3 h in the presence of GDPs; 3-DG (307 μM), 3,4-DGE (48 μM), 5-HMF (16 μM) and formaldehyde (12 μM), or in the presence of infusion fluids 2 and 3 with their respective controls (sf). E. coli-infected neutrophils were used as a positive control. Uninfected cells were used as a negative control. The presence of GDPs clearly suppressed secretion of both IL-6 and CXCL8 (see Supplementary Fig. 3). The results are means from six different blood donors. The statistical difference between GDP-treated neutrophils and the positive control was calculated with Mann–Whitney test/Student t test (*P < 0.05, **P < 0.01, ***P < 0.001)

To investigate the impact of GDPs on neutrophil function, we measured the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-mediated secretion of reactive oxygen species (ROS) from infected cells (see Supplementary Fig. 4). Formaldehyde and 3,4-DGE significantly inhibited neutrophil microbial killing, by 43% and 56%, respectively (P < 0.001), while 3-DG and 5-HMF suppressed neutrophil microbial killing by 35% and 23% (P < 0.01). Neutrophil capacity to kill bacteria was further inhibited with fluid 3 (57%) and to a lesser extent with fluid 2 (10%). The sterile filtered control fluids were not found to reduce neutrophil ROS secretion.

Discussion

All investigated glucose-containing infusion fluids contained high amounts of GDPs. Moreover, increased concentrations of GDPs were found in blood circulation of critically ill patients receiving standard postoperative fluid therapy. The amount of 3-DG in the serum of a healthy human is approximately 0.2 μM [26], and increases twofold with disease such as diabetes and threefold in uremia [26]. Before infusion, all patients had normal levels of 3-DG, but the concentration increased eightfold shortly after infusion of glucose-containing infusion fluids and did not reach the background level even after 9 h. In contrast, serum and urinary 3-DG levels were low in the control patients who received buffered saline. This finding suggests that the increased 3-DG found in serum of patients receiving the standard postoperative fluid therapy with glucose originated from the high amounts of GDPs found in these fluids. We did not succeed in measuring the amount of the more reactive GDPs, since these molecules bind to proteins immediately after infusion and their unbound concentrations were thus below the detection limit [12]. Therefore, none of the infused 3,4-DGE was detected in serum or in urine at the end of the study. Of the infused 3-DG in the glucose-containing infusion fluids, we found 2% unbound in serum and only 9.6% in urine at the end of our study. This means that 88% of the infused 3-DG is gone, possibly bound to serum proteins, giving rise to advanced glycation end products (AGEs) [13]. The serum amount of 5-HMF doubled during the experiment, and urinary secretion of this inert molecule increased fourfold. One explanation for the increased 5-HMF concentration might be that 3-DG is converted to 5-HMF through equilibrium with the reactive 3,4-DGE [17, 18]. This could explain the increased concentration of 5-HMF found in urine, but it also demonstrates that 3-DG is a reservoir for newly formed highly reactive 3,4-DGE.

There was a linear correlation between the amount of infused 3-DG and the increased formation of CML, a marker of AGE formation. Serum CML levels were low in the control patients receiving buffered saline in this study. The results are in good agreement with a recent publication by Humpert et al. [27] showing that human serum albumin (HSA) preparations for intravenous use contain high levels of CML. Furthermore, they found that the infusion of these CML-containing HSA preparations induced inflammation and caused increased mortality in experimental peritonitis. Furthermore, patients with renal failure accumulate 3-DG in serum due to impaired glucose metabolism and impaired renal clearance. In two recent studies, hemodialysis (HD) was shown to effectively remove AGEs and 3-DG, while an increase of this molecule was observed after PD treatment [28, 29]. This discrepancy was found to originate from the fluids used in the two modes of dialysis, i.e., PD fluids contain high amounts of GDPs while the HD fluids were low in GDPs. Levels of AGEs are also known to be significantly elevated in postoperative complications after major operations such as surgical coronary artery revascularization and renal transplantation [30, 31]. The patients in our study went through a broad range of fairly uncomplicated operations, but we found a restricted dissemination in serum CML concentration. This indicates that the increase is related to the infusion fluids rather than to the surgery.

Infusion fluids containing high levels of GDPs may have systemic effects resulting from local cytotoxic activity on blood vessels and blood cells, but also an indirect effect due to enhanced systemic AGE formation. Increased 3-DG has been shown to lead to a threefold increase in kidney lesions after 3 days in a rat model [32]. Among the patients in our study, we observed an eightfold increase in serum 3-DG after receiving 1.7 l of GDP-containing infusion fluid. In more critically ill patients, it is not unusual for patients to receive 4 l of infusion fluids every day, for 2 days or longer. The more reactive GDP, formaldehyde, is connected to various forms of cancer in humans [33], and Zwart et al. [34] showed that rats exposed to 10 μM formaldehyde experienced a significant increase of cell turnover. However, the best way to state the possible importance of GDPs in clinical practice is perhaps to demonstrate what happens when they are blocked. It is well known that reactive carbonyl compounds play an important role in the development of diabetic complications. A promising drug candidate for treatment of diabetic nephropathy is pyroxidamine, which is currently on the Food and Drug Administration (FDA) “fast track” for phase III clinical trials [35]. Pyroxidamine is a scavenger for reactive carbonyl compounds such as 3-DG [36], and has been shown in a phase II clinical study to ameliorate nephropathy [37, 38], enhance whole-body insulin sensitivity [39], increase creatinine clearance, and reduce inflammation and formation of AGEs. These data suggest that sterilization improvement leading to GDP removal from infusion fluids could be beneficial for insulin sensitivity and renal protection in intensive care patients.

Severely hyperglycemic patients typically suffer from complications such as infections and decreased wound healing. Recent studies have revealed that GDPs interfere with carbohydrate metabolism [40]. In this study, we found that the most reactive GDP, 3,4-DGE, was present at concentrations that could decrease neutrophil viability and affect cell function. Furthermore, neutrophil exposure to GDPs or the infusion fluids significantly inhibited secretion of cytokines involved in inflammatory conditions. These findings show that normal postoperative fluid treatment involves infusion of potentially dangerous fluids into patients. These observations are in good agreement with a study by Catalan et al. [11] showing that GDPs cause neutrophil apoptosis. We analyzed the oxidative burst in human neutrophils treated with GDPs or infusion fluids as a functional measurement of neutrophil function upon bacterial infection. We found that the oxidative burst was greatly inhibited both by GDPs and by the diluted infusion fluids. The ability of GDPs to impair microbial killing could thus contribute to the infection susceptibility and decreased wound healing that are observed in hyperglycemic patients.

The results of this study indicate that normal postoperative fluid treatment involves infusion of dangerously high concentrations of GDPs. New manufacturing techniques have reduced the amounts of GDPs in medical fluids, making these more biocompatible [17, 18]. It seems evident that the same approach in manufacturing should be introduced for fluids for intravenous use.

Notes

Acknowledgments

Supported, in part, by a Research Scientist Grant from the Swedish Medical Research Council (2005-7364 and 2008-5135). The employees of Gambro Lundia AB listed as authors participated with other authors in the study design, but did not participate in the collection, analysis, or interpretation of the data. The authors have not disclosed any potential conflicts of interest. We thank Dr. H. Janson for scientific support and Robert George Dewsnap for linguistic revision. We thank also Mrs. E. Svensson and Mrs. G. Forsbäck for excellent technical assistance and Mrs. A. Johansson for help with clinical material.

Open Access

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Supplementary material

134_2010_1873_MOESM1_ESM.doc (72 kb)
Supplementary material 1 (DOC 72 kb)
134_2010_1873_MOESM2_ESM.ppt (84 kb)
Supplementary material 2 (PPT 83.5 kb)

References

  1. 1.
    Iapichino G, Albicini M, Umbrello M, Sacconi F, Fermo I, Pavlovich R, Paroni R, Bellani G, Mistraletti G, Cugno M, Pesenti A, Gattinoni L (2008) Tight glycemic control does not affect asymmetric-dimethylarginine in septic patients. Intensive Care Med 34:1843–1850CrossRefPubMedGoogle Scholar
  2. 2.
    Michalia M, Kompoti M, Koutsikou A, Paridou A, Giannopoulou P, Trikka-Graphakos E, Clouva-Molyvdas P (2009) Diabetes mellitus is an independent risk factor for ICU-acquired bloodstream infections. Intensive Care Med 35:448–454CrossRefPubMedGoogle Scholar
  3. 3.
    Preiser JC, Devos P, Ruiz-Santana S, Melot C, Annane D, Groeneveld J, Iapichino G, Leverve X, Nitenberg G, Singer P, Wernerman J, Joannidis M, Stecher A, Chiolero R (2009) A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study. Intensive Care Med 35:1738–1748CrossRefPubMedGoogle Scholar
  4. 4.
    Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, Hebert PC, Heritier S, Heyland DK, McArthur C, McDonald E, Mitchell I, Myburgh JA, Norton R, Potter J, Robinson BG, Ronco JJ (2009) Intensive versus conventional glucose control in critically ill patients. N Engl J Med 360:1283–1297CrossRefPubMedGoogle Scholar
  5. 5.
    Wieslander AP, Nordin MK, Kjellstrand PT, Boberg UC (1991) Toxicity of peritoneal dialysis fluids on cultured fibroblasts, L-929. Kidney Int 40:77–79CrossRefPubMedGoogle Scholar
  6. 6.
    Linden T, Forsback G, Deppisch R, Henle T, Wieslander A (1998) 3-Deoxyglucosone, a promoter of advanced glycation end products in fluids for peritoneal dialysis. Perit Dial Int 18:290–293PubMedGoogle Scholar
  7. 7.
    Linden T, Cohen A, Deppisch R, Kjellstrand P, Wieslander A (2002) 3, 4-Dideoxyglucosone-3-ene (3, 4-DGE): a cytotoxic glucose degradation product in fluids for peritoneal dialysis. Kidney Int 62:697–703CrossRefPubMedGoogle Scholar
  8. 8.
    Conaway CC, Whysner J, Verna LK, Williams GM (1996) Formaldehyde mechanistic data and risk assessment: endogenous protection from DNA adduct formation. Pharmacol Ther 71:29–55CrossRefPubMedGoogle Scholar
  9. 9.
    Morgan LW, Wieslander A, Davies M, Horiuchi T, Ohta Y, Beavis MJ, Craig KJ, Williams JD, Topley N (2003) Glucose degradation products (GDP) retard remesothelialization independently of d-glucose concentration. Kidney Int 64:1854–1866CrossRefPubMedGoogle Scholar
  10. 10.
    Justo P, Sanz AB, Egido J, Ortiz A (2005) 3, 4-Dideoxyglucosone-3-ene induces apoptosis in renal tubular epithelial cells. Diabetes 54:2424–2429CrossRefPubMedGoogle Scholar
  11. 11.
    Catalan MP, Santamaria B, Reyero A, Ortiz A, Egido J, Ortiz A (2005) 3, 4-di-deoxyglucosone-3-ene promotes leukocyte apoptosis. Kidney Int 68:1303–1311CrossRefPubMedGoogle Scholar
  12. 12.
    Erixon M, Wieslander A, Linden T, Carlsson O, Jönsson JÅ, Simonsen O, Kjellstrand P (2007) 3, 4-DGE in peritoneal dialysis fluids cannot be found in plasma after infusion into the peritoneal cavity. Perit Dial Int 28:277–278Google Scholar
  13. 13.
    Zeier M, Schwenger V, Deppisch R, Haug U, Weigel K, Bahner U, Wanner C, Schneider H, Henle T, Ritz E (2003) Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int 63:298–305CrossRefPubMedGoogle Scholar
  14. 14.
    Sarafidis PA, Whaley-Connell A, Sowers JR, Bakris GL (2006) Cardiometabolic syndrome and chronic kidney disease: what is the link? J Cardiometab Syndr 1:58–65CrossRefPubMedGoogle Scholar
  15. 15.
    Lin CL, Wang FS, Kuo YR, Huang YT, Huang HC, Sun YC, Kuo YH (2006) Ras modulation of superoxide activates ERK-dependent fibronectin expression in diabetes-induced renal injuries. Kidney Int 69:1593–1600CrossRefPubMedGoogle Scholar
  16. 16.
    Garcia-Lopez E, Carrero JJ, Suliman ME, Lindholm B, Stenvinkel P (2007) Risk factors for cardiovascular disease in patients undergoing peritoneal dialysis. Perit Dial Int 27 suppl 2:S205–209Google Scholar
  17. 17.
    Erixon M, Wieslander A, Linden T, Carlsson O, Forsback G, Svensson E, Jonsson JA, Kjellstrand P (2005) Take care in how you store your PD fluids: actual temperature determines the balance between reactive and non-reactive GDPs. Perit Dial Int 25:583–590PubMedGoogle Scholar
  18. 18.
    Erixon M, Wieslander A, Linden T, Carlsson O, Forsback G, Svensson E, Jonsson JA, Kjellstrand P (2006) How to avoid glucose degradation products in peritoneal dialysis fluids. Perit Dial Int 26:490–497PubMedGoogle Scholar
  19. 19.
    Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C, Passlick-Deetjen J (2004) The Euro-Balance trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 66:408–418CrossRefPubMedGoogle Scholar
  20. 20.
    Schmitt CP, von Heyl D, Rieger S, Arbeiter K, Bonzel KE, Fischbach M, Misselwitz J, Pieper AK, Schaefer F (2007) Reduced systemic advanced glycation end products in children receiving peritoneal dialysis with low glucose degradation product content. Nephrol Dial Transplant 22:2038–2044CrossRefPubMedGoogle Scholar
  21. 21.
    Rippe B, Simonsen O, Heimburger O, Christensson A, Haraldsson B, Stelin G, Weiss L, Nielsen FD, Bro S, Friedberg M, Wieslander A (2001) Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 59:348–357CrossRefPubMedGoogle Scholar
  22. 22.
    Montenegro J, Saracho R, Gallardo I, Martinez I, Munoz R, Quintanilla N (2007) Use of pure bicarbonate-buffered peritoneal dialysis fluid reduces the incidence of CAPD peritonitis. Nephrol Dial Transplant 22:1703–1708CrossRefPubMedGoogle Scholar
  23. 23.
    Lee HY, Choi HY, Park HC, Seo BJ, Do JY, Yun SR, Song HY, Kim YH, Kim YL, Kim DJ, Kim YS, Kim MJ, Shin SK (2006) Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome. Nephrol Dial Transplant 21:2893–2899CrossRefPubMedGoogle Scholar
  24. 24.
    Wieslander AP, Andren AH, Nilsson-Thorell C, Muscalu N, Kjellstrand PT, Rippe B (1995) Are aldehydes in heat-sterilized peritoneal dialysis fluids toxic in vitro? Perit Dial Int 15:348–352PubMedGoogle Scholar
  25. 25.
    Ulbricht RJ, Northup SJ, Thomas JA (1984) A review of 5-hydroxymethylfurfural (HMF) in parenteral solutions. Fundam Appl Toxicol 4:843–853CrossRefPubMedGoogle Scholar
  26. 26.
    Kusunoki H, Miyata S, Ohara T, Liu BF, Uriuhara A, Kojima H, Suzuki K, Miyazaki H, Yamashita Y, Inaba K, Kasuga M (2003) Relation between serum 3-deoxyglucosone and development of diabetic microangiopathy. Diabetes Care 26:1889–1894CrossRefPubMedGoogle Scholar
  27. 27.
    Humpert PM, Lukic IK, Thorpe SR, Hofer S, Awad EM, Andrassy M, Deemer EK, Kasper M, Schleicher E, Schwaninger M, Weigand MA, Nawroth PP, Bierhaus A (2009) AGE-modified albumin containing infusion solutions boosts septicaemia and inflammation in experimental peritonitis. J Leukoc Biol 86:589–597CrossRefPubMedGoogle Scholar
  28. 28.
    Agalou S, Ahmed N, Thornalley PJ, Dawnay A (2005) Advanced glycation end product free adducts are cleared by dialysis. Ann NY Acad Sci 1043:734–739CrossRefPubMedGoogle Scholar
  29. 29.
    Agalou S, Ahmed N, Babaei-Jadidi R, Dawnay A, Thornalley PJ (2005) Profound mishandling of protein glycation degradation products in uremia and dialysis. J Am Soc Nephrol 16:1471–1485CrossRefPubMedGoogle Scholar
  30. 30.
    Simm A, Wagner J, Gursinsky T, Nass N, Friedrich I, Schinzel R, Czeslik E, Silber RE, Scheubel RJ (2007) Advanced glycation endproducts: a biomarker for age as an outcome predictor after cardiac surgery? Exp Gerontol 42:668–675CrossRefPubMedGoogle Scholar
  31. 31.
    Franke S, Muller A, Sommer M, Busch M, Kientsch-Engel R, Stein G (2003) Serum levels of total homocysteine, homocysteine metabolites and of advanced glycation end-products (AGEs) in patients after renal transplantation. Clin Nephrol 59:88–97PubMedGoogle Scholar
  32. 32.
    Brown TR, Su B, Brown KA, Schwartz MA, Tobia AM, Kappler F (2003) Modulation of in vivo 3-deoxyglucosone levels. Biochem Soc Trans 31:1433–1437CrossRefPubMedGoogle Scholar
  33. 33.
    Costa S, Coelho P, Costa C, Silva S, Mayan O, Santos LS, Gaspar J, Teixeira JP (2008) Genotoxic damage in pathology anatomy laboratory workers exposed to formaldehyde. Toxicology 252:40–48CrossRefPubMedGoogle Scholar
  34. 34.
    Zwart A, Woutersen RA, Wilmer JW, Spit BJ, Feron VJ (1988) Cytotoxic and adaptive effects in rat nasal epithelium after 3-day and 13-week exposure to low concentrations of formaldehyde vapour. Toxicology 51:87–99CrossRefPubMedGoogle Scholar
  35. 35.
    Williams ME (2006) New potential agents in treating diabetic kidney disease: the fourth act. Drugs 66:2287–2298CrossRefPubMedGoogle Scholar
  36. 36.
    Chetyrkin SV, Zhang W, Hudson BG, Serianni AS, Voziyan PA (2008) Pyridoxamine protects proteins from functional damage by 3-deoxyglucosone: mechanism of action of pyridoxamine. Biochemistry 47:997–1006CrossRefPubMedGoogle Scholar
  37. 37.
    Nakamura S, Li H, Adijiang A, Pischetsrieder M, Niwa T (2007) Pyridoxal phosphate prevents progression of diabetic nephropathy. Nephrol Dial Transplant 22:2165–2174CrossRefPubMedGoogle Scholar
  38. 38.
    Alderson NL, Chachich ME, Youssef NN, Beattie RJ, Nachtigal M, Thorpe SR, Baynes JW (2003) The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney Int 63:2123–2133CrossRefPubMedGoogle Scholar
  39. 39.
    Muellenbach EA, Diehl CJ, Teachey MK, Lindborg KA, Archuleta TL, Harrell NB, Andersen G, Somoza V, Hasselwander O, Matuschek M, Henriksen EJ (2008) Interactions of the advanced glycation end product inhibitor pyridoxamine and the antioxidant alpha-lipoic acid on insulin resistance in the obese Zucker rat. Metabolism 57:1465–1472CrossRefPubMedGoogle Scholar
  40. 40.
    Berstein LM, Vasilyev DA, Poroshina TE, Kovalenko IG (2006) Glucose-induced effects and joker function of glucose: endocrine or genotoxic prevalence? Horm Metab Res 38:650–655CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s) 2010

Authors and Affiliations

  • Anna Bryland
    • 1
  • Marcus Broman
    • 2
  • Martin Erixon
    • 3
  • Bengt Klarin
    • 2
  • Torbjörn Lindén
    • 4
  • Hans Friberg
    • 2
  • Anders Wieslander
    • 4
  • Per Kjellstrand
    • 4
  • Claudio Ronco
    • 5
  • Ola Carlsson
    • 4
  • Gabriela Godaly
    • 6
  1. 1.Department of NephrologyLund UniversityLundSweden
  2. 2.Department of Anaesthesiology and Intensive CareLund University HospitalLundSweden
  3. 3.Department of Analytical ChemistryLund UniversityLundSweden
  4. 4.Gambro Lundia ABLundSweden
  5. 5.Department of NephrologySt. Bortolo HospitalVicenzaItaly
  6. 6.Department of Microbiology, Immunology and GlycobiologyLund UniversityLundSweden

Personalised recommendations